| Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA DA Nathanson, B Gini, J Mottahedeh, K Visnyei, T Koga, G Gomez, ... Science 343 (6166), 72-76, 2014 | 629 | 2014 |
| Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers CM Blakely, TBK Watkins, W Wu, B Gini, JJ Chabon, CE McCoach, ... Nature genetics 49 (12), 1693-1704, 2017 | 507 | 2017 |
| Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis G Constantin, S Marconi, B Rossi, S Angiari, L Calderan, E Anghileri, ... Stem cells 27 (10), 2624-2635, 2009 | 499 | 2009 |
| An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR–dependent pathway D Guo, F Reinitz, M Youssef, C Hong, D Nathanson, D Akhavan, D Kuga, ... Cancer discovery 1 (5), 442-456, 2011 | 473 | 2011 |
| mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc K Masui, K Tanaka, D Akhavan, I Babic, B Gini, T Matsutani, A Iwanami, ... Cell metabolism 18 (5), 726-739, 2013 | 421 | 2013 |
| Oncogenic EGFR signaling activates an mTORC2–NF-κB pathway that promotes chemotherapy resistance K Tanaka, I Babic, D Nathanson, D Akhavan, D Guo, B Gini, J Dang, ... Cancer discovery 1 (6), 524-538, 2011 | 337 | 2011 |
| Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment K Tanaka, T Sasayama, Y Irino, K Takata, H Nagashima, N Satoh, ... The Journal of clinical investigation 125 (4), 1591-1602, 2015 | 242 | 2015 |
| mTORC2 regulates amino acid metabolism in cancer by phosphorylation of the cystine-glutamate antiporter xCT Y Gu, CP Albuquerque, D Braas, W Zhang, GR Villa, J Bi, S Ikegami, ... Molecular cell 67 (1), 128-138. e7, 2017 | 187 | 2017 |
| EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer I Babic, ES Anderson, K Tanaka, D Guo, K Masui, B Li, S Zhu, Y Gu, ... Cell metabolism 17 (6), 1000-1008, 2013 | 183 | 2013 |
| Single-cell phosphoproteomics resolves adaptive signaling dynamics and informs targeted combination therapy in glioblastoma W Wei, YS Shin, M Xue, T Matsutani, K Masui, H Yang, S Ikegami, Y Gu, ... Cancer cell 29 (4), 563-573, 2016 | 179 | 2016 |
| Inactivation of Capicua drives cancer metastasis RA Okimoto, F Breitenbuecher, VR Olivas, W Wu, B Gini, M Hofree, ... Nature genetics 49 (1), 87-96, 2017 | 153 | 2017 |
| A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments K Masui, B Gini, J Wykosky, C Zanca, PS Mischel, FB Furnari, ... Carcinogenesis 34 (4), 725-738, 2013 | 143 | 2013 |
| Novel autoantigens recognized by CSF IgG from Hashimoto's encephalitis revealed by a proteomic approach B Gini, L Laura, C Riccardo, C Laura, S Marconi, E Anghileri, ... Journal of neuroimmunology 196 (1-2), 153-158, 2008 | 80 | 2008 |
| PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies A Iwanami, B Gini, C Zanca, T Matsutani, A Assuncao, A Nael, J Dang, ... Proceedings of the National Academy of Sciences 110 (11), 4339-4344, 2013 | 73 | 2013 |
| Transketolase and 2′, 3′-cyclic-nucleotide 3′-phosphodiesterase type I isoforms are specifically recognized by IgG autoantibodies in multiple sclerosis patients L Lovato, R Cianti, B Gini, S Marconi, L Bianchi, A Armini, E Anghileri, ... Molecular & Cellular Proteomics 7 (12), 2337-2349, 2008 | 64 | 2008 |
| The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas B Gini, C Zanca, D Guo, T Matsutani, K Masui, S Ikegami, H Yang, ... Clinical Cancer Research 19 (20), 5722-5732, 2013 | 55 | 2013 |
| Different content of chitin-like polysaccharides in multiple sclerosis and Alzheimer's disease brains S Sotgiu, S Musumeci, S Marconi, B Gini, B Bonetti Journal of neuroimmunology 197 (1), 70-73, 2008 | 52 | 2008 |
| The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance DR Caswell, P Gui, MK Mayekar, EK Law, O Pich, C Bailey, J Boumelha, ... Nature Genetics 56 (1), 60-73, 2024 | 27 | 2024 |
| Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer CMB B Gini, N Thomas Journal of Thoracic Disease 12 (5), 2883-2895, 2020 | 27 | 2020 |
| Targeted cancer therapy induces APOBEC fueling the evolution of drug resistance M Mayekar, D Caswell, N Vokes, EK Law, W Wu, W Hill, E Gronroos, ... Cancer Research 82 (12_Supplement), 2197-2197, 2022 | 19 | 2022 |
Paul MischelStanford University在 stanford.edu 的电子邮件经过验证
